The role of cytokines in the initiation and progression of myelofibrosis

Cytokine and Growth Factor Reviews

Volumn 24, Issue 2, 2013, Pages 133-145

  Hasselbalch, Hans C ^a  

^a ROSKILDE HOSPITAL   (Denmark)

Author keywords

Chronic inflammation; Cytokines; Interferon alpha2; JAK inhibitor; Myelofibrosis; Myeloproliferative neoplasms; Statins

Indexed keywords

BUSULFAN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON; RUXOLITINIB; STAT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; GENE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DYSREGULATION; JAK2 GENE; LOW DRUG DOSE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTHEMIA; TREATMENT RESPONSE;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; STAT TRANSCRIPTION FACTORS;

EID: 84875279909     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.01.004     Document Type: Review

References (171)

1. Dinarello C.A. Historical insights into cytokines. European Journal of Immunology 2007, 37(Suppl. 1):S34-S45.
2. Brancato S.K., Albina J.E. Wound macrophages as key regulators of repair: origin, phenotype, and function. American Journal of Pathology 2011, 178:19-25.
3. Daley J.M., Brancato S.K., Thomay A.A., Reichner J.S., Albina J.E. The phenotype of murine wound macrophages. Journal of Leukocyte Biology 2010, 87:59-67.
4. Adamson R. Role of macrophages in normal wound healing: an overview. Journal of Wound Care 2009, 18:349-351.
5. Guo S., Dipietro L.A. Factors affecting wound healing. Journal of Dental Research 2010, 89:219-229.
6. Gosain A., DiPietro L.A. Aging and wound healing. World Journal of Surgery 2004, 28:321-326.
7. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiological Reviews 2003, 83:835-870.
8. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
9. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986, 315:1650-1659.
10. Wu Y., Zhou B.P. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009, 8:3267-3273.
11. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 2004, 4:71-78.
12. Porta C., Subhra Kumar B., Larghi P., Rubino L., Mancino A., Sica A. Tumor promotion by tumor-associated macrophages. Advances in Experimental Medicine and Biology 2007, 604:67-86.
13. Hagemann T., Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods in Molecular Biology 2009, 512:325-332.
14. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004, 306:966-968.
15. Karin M., Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 2005, 5:749-759.
16. DiDonato J.A., Mercurio F., Karin M. NF-κB and the link between inflammation and cancer. Immunological Reviews 2012, 246:379-400.
17. Campbell P.J., Green A.R. The myeloproliferative disorders. New England Journal of Medicine 2006, 355:2452-2466.
18. Hasselbalch H.C. Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leukemia Research 2012, 10.1016/j.leukres.2012.10.020.
19. Hasselbalch H.C. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood 2012, 119:3219-3225.
20. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
21. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., et al. Mutation in TET2 in myeloid cancers. New England Journal of Medicine 2009, 360:2289-2301.
22. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics 2010, 42:722-726.
23. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
24. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
25. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118:167-176.
26. Rumi E., Harutyunyan A., Elena C., Pietra D., Klampfl T., Bagienski K., et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology 2011, 86:974-979.
27. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. European Journal of Haematology 2011, 87:54-60.
28. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leukemia Research 2012, 36(11):1387-1392.
29. Skov V., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., Kruse T.A., et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology 2012, 40(9):771-780.
30. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of Clinical Oncology 2011, 29:1356-1363.
31. Vaidya R., Gangat N., Jimma T., Finke C.M., Lasho T.L., Pardanani A., et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. American Journal of Hematology 2012, 87(11):1003-1005.
32. Murray P.J. The JAK-STAT signaling pathway: input and output integration. Journal of Immunology 2007, 178:2623-2629.
33. Schindler C., Plumlee C. Interferons pen the JAK-STAT pathway. Seminars in Cell and Developmental Biology 2008, 19:311-318.
34. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
35. Neubauer H., Cumano A., Müller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
36. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
37. Quintas-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
38. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer 2007, 7:673-683.
39. Vainchenker W., Dusa A., Constantinescu S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Seminars in Cell and Developmental Biology 2008, 19:385-393.
40. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
41. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
42. Vannucchi A.M., Guglielmelli P., Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA: A Cancer Journal for Clinicians 2009, 59:171-191.
43. Mui A.L. The role of STATs in proliferation, differentiation, and apoptosis. Cellular and Molecular Life Sciences 1999, 55:1547-1558.
44. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
45. Seavey M.M., Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology 2011, 83:1136-1145.
46. Zhang F., Li C., Halfter H., Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003, 22:894-905.
47. Aoki Y., Feldman G.M., Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101:1535-1542.
48. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009, 9:798-809.
49. Jeong E.G., Kim M.S., Nam H.K., Min C.K., Lee S., Chung Y.J., et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clinical Cancer Research 2008, 14:3716-3721.
50. Vainchenker W., Constantinescu S.N. JAK/STAT signaling in hematological malignancies. Oncogene 2012, 10.1038/onc.2012.347.
51. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
52. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 2005, 352:1779-1790.
53. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
54. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
55. Vainchenker W., Delhommeau F., Constantinescu S.N., Bernard O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 188:1723-1735.
56. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine 2006, 3:e270.
57. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141-149.
58. Kjaer L., Westman M., Hasselbalch Riley C., Hogdall E., Weis Bjerrum O., Hasselbalch H. A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. PLoS ONE 2012, 7:e33100.
59. Jones A.V., Chase A., Silver R.T., Oscier D., Zoi K., Wang Y.L., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics 2009, 41:446-449.
60. Olcaydu D., Harutyunyan A., Jager R., Berg T., Gisslinger B., Pabinger I., et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics 2009, 41:450-454.
61. Tefferi A. Myelofibrosis with myeloid metaplasia. New England Journal of Medicine 2000, 342:1255-1265.
62. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clinical Cancer Research 2008, 14:6735-6741.
63. Hsu H.C., Tsai W.H., Jiang M.L., Ho C.H., Hsu M.L., Ho C.K., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. Journal of Laboratory and Clinical Medicine 1999, 134:392-397.
64. Panteli K.E., Hatzimichael E.C., Bouranta P.K., Katsaraki A., Seferiadis K., Stebbing J., et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British Journal of Haematology 2005, 130:709-715.
65. Ho C.L., Lasho T.L., Butterfield J.H., Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leukemia Research 2007, 31:1389-1392.
66. Boissinot M., Cleyrat C., Vilaine M., Jacques Y., Corre I., Hermouet S. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. Oncogene 2011, 30:990-1001.
67. Pardanani A., Begna K., Finke C., Lasho T., Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. American Journal of Hematology 2011, 86:343-345.
68. Witzel I.D., Milde-Langosch K., Wirtz R.M., Roth C., Ihnen M., Mahner S., et al. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. Journal of Cancer Research and Clinical Oncology 2010, 136:1709-1718.
69. Tefferi A. How I treat myelofibrosis. Blood 2011, 117:3494-3504.
70. Le Bousse-Kerdiles M.C., Martyre M.C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Annals of Hematology 1999, 78:437-444.
71. Hasselbalch H.C., Larsen T.S., Riley C.H., Jensen M.K., Kiladjian J.J. Interferon alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Current Drug Targets 2011, 12:392-419.
72. Bock O., Höftmann J., Theophile K., Hussein K., Wiese B., Schlué J., et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. American Journal of Pathology 2008, 172:951-960.
73. Chang V.T., Yook C., Rameshwar P. Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis. Leukemia and Lymphoma 2012, 10.3109/10428194.2012.722218.
74. Papadantonakis N., Matsuura S., Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 2012, 120:1774-1781.
75. Hoermann G., Cerny-Reiterer S., Herrmann H., Blatt K., Bilban M., Gisslinger H., et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB Journal 2012, 26:894-906.
76. Wang X., Prakash S., Lu M., Tripodi J., Ye F., Najfeld V., et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 2012, 122:3888-3899.
77. Konoplev S., Hsieh P.P., Chang C.C., Medeiros L.J., Lin P. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. Human Pathology 2007, 38:1760-1763.
78. Li J., Sejas D.P., Zhang X., Qiu Y., Nattamai K.J., Rani R., et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. Journal of Clinical Investigation 2007, 117:3283-3295.
79. Fleischman A.G., Aichberger K.J., Luty S.B., Bumm T.G., Petersen C.L., Doratotaj S., et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118:6392-6398.
80. Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clinical Cancer Research 2010, 16:1988-1996.
81. Kristinsson S.Y., Landgren O., Samuelsson J., Björkholm M., Goldin L.R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95:1216-1220.
82. Vannucchi A.M., Masala G., Antonioli E., Chiara Susini M., Guglielmelli P., Pieri L., et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiology, Biomarkers and Prevention 2009, 18:2068-2073.
83. Frederiksen H., Farkas D.K., Christiansen C.F., Hasselbalch H.C., Sorensen H.T. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011, 118:6515-6520.
84. Susini M.C., Masala G., Antonioli E., Pieri L., Guglielmelli P., Palli D., et al. Risk of second cancers in chronic myeloproliferative neoplasms. Blood 2012, 119:3861-3862. [author reply 3862-3].
85. Hermouet S., Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?. Haematologica 2011, 96:1575-1579.
86. Nielsen C., Birgens H.S., Nordestgaard B.G., Kjaer L., Bojesen S.E. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 2011, 96:450-453.
87. Dong M., Blobe G.C. Role of transforming growth factor-β in hematologic malignancies. Blood 2006, 107:4589-4596.
88. Johnson B.F., Clay T.M., Hobeika A.C., Lyerly H.K., Morse M.A. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opinion on Biological Therapy 2007, 7:449-460.
89. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends in Immunology 2010, 31:220-227.
90. Plo I., Nakatake M., Malivert L., de Villartay J.P., Giraudier S., Villeval J.L., et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112:1402-1412.
91. Vilaine M., Olcaydu D., Harutyunyan A., Bergeman J., Tiab M., Ramee J.F., et al. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood 2011, 118:6468-6470.
92. Marchioli R., Finazzi G., Landolfi R., Kutti J., Gisslinger H., Patrono C., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology 2005, 23:2224-2232.
93. Barosi G., Rosti V., Vannucchi A.M. Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy 2011, 12(10):1597-1611.
94. Alchalby H., Badbaran A., Zabelina T., Kobbe G., Hahn J., Wolff D., et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010, 116:3572-3581.
95. Gupta V., Hari P., Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012, 120(7):1367-1379.
96. Silver R.T. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988, 2:403.
97. Bellucci S., Harousseau J.L., Brice P., Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988, 2:960-961.
98. Linkesch W., Gisslinger H., Ludwig H., Flener R., Sinzinger H. Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses. Acta Medica Austriaca 1985, 12:123-127. [in German].
99. Silver R.T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 2006, 107:451-458.
100. Samuelsson J., Hasselbalch H., Bruserud O., Temerinac S., Brandberg Y., Merup M., et al. A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006, 106:2397-2405.
101. Kiladjian J.J., Cassinat B., Turlure P., Cambier N., Roussel M., Bellucci S., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 2006, 108:2037-2040.
102. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
103. Quintás-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology 2009, 27:5418-5424.
104. Larsen T.S., Møller M.B., de Stricker K., Nørgaard P., Samuelsson J., Marcher C., et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009, 14:331-334.
105. Turlure P., Cambier N., Roussel M., Bellucci S., Zini J., Rain J., et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial. Blood 2011, 118. [ASH abstract 280].
106. Silver R.T., Vandris K. Recombinant interferon alpha (rIFN α-2b) may retard progression of early primary myelofibrosis. Leukemia 2009, 23:1366-1369.
107. Ianotto J.C., Kiladjian J.J., Demory J.L., Roy L., Boyer F., Rey J., et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). British Journal of Haematology 2009, 146:223-225.
108. Silver R.T., Vandris K., Goldman J.J. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011, 117:6669-6672.
109. Gowin K., Thapaliya P., Samuelsson J., Harrison C., Radia D., Andreasson B., et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012, 97(10):1570-1573.
110. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22:1990-1998.
111. Hasselbalch H.C. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology 2011, 4:637-655.
112. Kiladjian J.J., Mesa R.A., Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011, 117:4706-4715.
113. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Review of Hematology; in press.
114. Carlo-Stella C., Cazzola M., Gasner A., Barosi G., Dezza L., Meloni F., et al. Effects of recombinant α and γ interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987, 70:1014-1019.
115. Castello G., Lerza R., Cerruti A., Cavallini D., Bogliolo G., Pannacciulli I. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. British Journal of Haematology 1994, 87:621-623.
116. Wang Q., Miyakawa Y., Fox N., Kaushansky K. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000, 96:2093-2099.
117. Tilg H., Peschel C. Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Leukemia and Lymphoma 1996, 23:55-60.
118. Tilg H., Mier J.W., Vogel W., Aulitzky W.E., Wiedermann C.J., Vannier E., et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. Journal of Immunology 1993, 150:4687-4692.
119. Huang Y., Blatt L.M., Taylor M.W. Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. Journal of Interferon and Cytokine Research 1995, 15:317-321.
120. Aulitzky W.E., Peschel C., Despres D., Aman J., Trautman P., Tilg H., et al. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Annals of Hematology 1993, 67:205-211.
121. Dinarello C.A. A clinical perspective of IL-1β as the gatekeeper of inflammation. European Journal of Immunology 2011, 41:1203-1217.
122. Chuen C.K., Li K., Yang M., Fok T.F., Li C.K., Chui C.M., et al. Interleukin-1β up-regulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells. Journal of Laboratory and Clinical Medicine 2004, 143:75-88.
123. Oliveira I.C., Sciavolino P.J., Lee T.H., Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9049-9053.
124. Aman M.J., Rudolf G., Goldschmitt J., Aulitzky W.E., Lam C., Huber C., et al. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood 1993, 82:2371-2378.
125. Lucia E., Recchia A.G., Gentile M., Bossio S., Vigna E., Mazzone C., et al. Janus kinase 2 inhibitors in myeloproliferative disorders. Expert Opinion on Investigational Drugs 2011, 20:41-59.
126. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine 2012, 366:799-807.
127. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine 2012, 366:787-798.
128. Harrison C., Kiladjian J., Gisslinger H., Passamonti F., Squires M., Knoops L., et al. Association of cytokine levels and reductions in spleen size in COMFORT-II: a phase 3 study comparing ruxolitinib with best available therapy (BAT). Haematologica 2012, 97(s1). [EHA abstract 0379].
129. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine 2010, 363:1117-1127.
130. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.
131. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R.M., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology 2011, 29:789-796.
132. Talpaz M., Jamieson C., Gabrail N., Lebedinsky C., Gao G., Liu F., et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. Blood 2012, 118. [ASH abstract 2837].
133. Santos F.P., Kantarjian H.M., Jain N., Manshouri T., Thomas D.A., Garcia-Manero G., et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136.
134. Tyner J.W., Bumm T.G., Deininger J., Wood L., Aichberger K.J., Loriaux M.M., et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010, 115:5232-5240.
135. Pardanani A., Gotlib J., Jamieson C., Cortes J., Talpaz M., Stone R., et al. SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011, 119. [ASH abstract 3838].
136. Vannucchi A., Kiladjian J.J., Gisslinger H., Passamonti F., Al-Ali H., Sirulnik A., et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase 3 study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). Haematologica 2012, 97(s1):151. [EHA abstract and poster 0373].
137. Kreipe H., Busche G., Bock O., Hussein K. Myelofibrosis: molecular and cell biological aspects. Fibrogenesis and Tissue Repair 2012, 5.
138. Le Bousse-Kerdiles M.C. Primary myelofibrosis and the " bad seeds in bad soil" concept. Fibrogenesis and Tissue Repair 2012, 5.
139. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., Uzan G., Jasmin C., Martyre M.C., et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008, 112:3026-3035.
140. Manshouri T., Estrov Z., Quintás-Cardama A., Burger J., Zhang Y., Livun A., et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Research 2011, 71:3831-3840.
141. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
142. Burger J.A. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Current Opinion in Oncology 2012, 24(6):643-649.
143. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
144. Ayala F., Dewar R., Kieran M., Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009, 23:2233-2241.
145. Essers M.A., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
146. Riley C.H., Jensen M.K., Brimnes M.K., Hasselbalch H.C., Bjerrum O.W., Straten P.T., et al. Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood 2011, 118:2170-2173.
147. Swierczek S., Kelley T.W., King K.Y., Ching-Chieh S., Hickman K., Kim S.J., et al. Salutary effect of pegylated interferon-a in PV and ET as evaluated by quantitation of Pre-JAK2V617F and JAK2V617F-bearing stem cells and granulocytes and correlation with circulating regulatory T Cells and HSC cell cycle status. ASH Annual Meeting Abstracts 2012, 120:807.
148. Farnault L., Sanchez C., Baier C., Le Treut T., Costello R.T. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clinical and Developmental Immunology 2012, 2012:421702.
149. Gersuk G.M., Carmel R., Pattamakom S., Challita P.M., Rabinowitz A.P., Pattengale P.K. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. Natural Immunity 1993, 12:136-151.
150. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine 2005, 11:1314-1321.
151. Wang W., Edington H.D., Rao U.N., Jukic D.M., Land S.R., Ferrone S., et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b. Clinical Cancer Research 2007, 13:1523-1531.
152. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry 2009, 107:600-608.
153. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
154. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology 2009, 5:601-612.
155. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research 2008, 14:4500-4510.
156. Dickinson M., Ritchie D., DeAngelo D.J., Spencer A., Ottmann O.G., Fischer T., et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British Journal of Haematology 2009, 147:97-101.
157. DeAngelo D.J., Tefferi A., Fiskus W., Mesa R.A., Paley C.S., Wadleigh M., et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor, in patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. Blood 2010, 116. [ASH abstract 630].
158. Baffert F., Evrot E., Ebel N., Rowlli C., Andraos R., Qian Z., et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2 V617F-driven disease. Blood 2011, 118. [ASH abstract 798].
159. Novotny-Diermayr V., Hart S., Goh K.C., Cheong A., Ong L.C., Hentze H., et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer Journal 2012, 2:e69.
160. Hasselbalch H.C., Riley C.H. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. Leukemia Research 2006, 30:1217-1225.
161. Griner L.N., McGraw K.L., Johnson J.O., List A.F., Reuther G.W. A mechanistic rationale for the use of statins to enhance JAK Inhibitor therapy in MPNs. Blood 2011, 118. [ASH abstract 2816].
162. Griner L.N., McGraw K.L., Johnson J.O., List A.F., Reuther G.W. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. British Journal of Haematology 2012, 10.1111/bjh.12103.
163. Hasselbalch H.C. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. Leukemia Research 2009, 33:11-18.
164. Hasselbalch H.C., Kiladjian J.J., Silver R.T. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Journal of Clinical Oncology 2011, 29:e564-e565.
165. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011, 29(5):573-582.
166. Hermouet S., Leveau C., Vilaine M. Inflammation and clone evolution in myeloproliferative neoplasms: Interest of combining drugs that target key cytokines with different signaling pathways. Blood 2012, E-Letter published March 1.
167. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007, 109(1):68-76.
168. Mesa R.A., Schwager S., Radia D., Cheville A., Hussein K., Niblack J., et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research 2009, 33(9):1199-1203.
169. Scherber R., Dueck A.C., Johansson P., Barbui T., Barosi G., Vannucchi A.M., et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011, 118(2):401-408.
170. Johansson P., Mesa R., Scherber R., Abelsson J., Samuelsson J., Birgegard G., et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leukemia and Lymphoma 2012, 53:441-444.
171. Emanuel R.M., Dueck A.C., Geyer H.L., Kiladjian J.J., Slot S., Zweegman S., et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology 2012, 33:4098-4103. 10.1200/JCO.2012.42.3863.